MiR-590-3p Attenuates Acute Kidney Injury by Inhibiting Tumor Necrosis Factor Receptor-Associated Factor 6 in Septic Mice
- 137 Downloads
Previous studies have been indicated that tumor necrosis factor receptor-associated factor 6 (TRAF6)-induced inflammation leads to acute kidney injury (AKI). How microRNA (miR) contributes to this process is poorly defined. The aim of this study was to investigate whether miR-590-3p regulated lipopolysaccharide (LPS)-induced inflammatory response by inhibiting TRAF6. LPS-induced septic mice were treated with adenovirus expressing miR-590-3p (ad-miR-590-3p) via tail-vein injection. AKI was evaluated by examining serum cystatin C (CysC), serum β2-microglobulin (β2-MG), and blood urea nitrogen (BUN). The mRNA and protein levels were assayed by RT-qPCR and western blotting, respectively. The proliferation of podocytes was monitored using the MTT assay. Cell apoptosis was analyzed by flow cytometry. Survival outcomes in ad-miR-590-3p-transfected septic mice were markedly improved compared with mice with LPS-induced sepsis. Ad-miR-590-3p transfection significantly attenuated LPS-induced AKI, which was reflected by an improved glomerular filtration rate (GFR) as determined by measuring CysC, β2-MG, and BUN. Moreover, we observed that miR-590-3p was a novel regulator of TRAF6, binding to its 3′-untranslated regions (3′-UTRs). In vitro, a miR-590-3p gain-of-function mutation blocked LPS-induced podocyte growth inhibition and apoptosis, as well as overactivation of the inflammatory response. miR-590-3p has the ability to suppress LPS-induced AKI and podocyte apoptosis by targeting TRAF6. This might provide a novel strategy for the treatment of LPS-induced renal injuries.
KEY WORDSmiR-590-3p sepsis AKI TRAF6 inflammatory response apoptosis
We give thanks to the Department of Pathology, Wuhan Third Hospital of Wuhan University to provide technical support.
Compliance with Ethical Standards
The experiment was approved by the Ethics Committee of the Wuhan three hospital of Wuhan University (Wuhan, China) and performed in accordance with its guidelines.
Conflict of Interest
The authors declare that they have no competing interests.
- 2.Bhargava, R., C.J. Altmann, A. Andres-Hernando, R.G. Webb, K. Okamura, Y. Yang, S. Falk, E.P. Schmidt, and S. Faubel. 2013. Acute lung injury and acute kidney injury are established by four hours in experimental sepsis and are improved with pre, but not post, sepsis administration of TNF-alpha antibodies. PLoS One 8: e79037.CrossRefGoogle Scholar
- 7.Emmerich, C.H., A. Ordureau, S. Strickson, J.S. Arthur, P.G. Pedrioli, D. Komander, and P. Cohen. 2013. Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains. Proceedings of the National Academy of Sciences of the United States of America 110: 15247–15252.CrossRefGoogle Scholar
- 9.Gao, M., X. Wang, X. Zhang, T. Ha, H. Ma, L. Liu, J.H. Kalbfleisch, X. Gao, R.L. Kao, D.L. Williams, and C. Li. 2015. Attenuation of cardiac dysfunction in polymicrobial sepsis by microRNA-146a is mediated via targeting of IRAK1 and TRAF6 expression. Journal of Immunology 195: 672–682.CrossRefGoogle Scholar
- 11.He, P.P., X.P. Ouyang, Y.Y. Tang, L. Liao, Z.B. Wang, Y.C. Lv, G.P. Tian, G.J. Zhao, L. Huang, F. Yao, W. Xie, Y.L. Tang, W.J. Chen, M. Zhang, Y. Li, J.F. Wu, J. Peng, X.Y. Liu, X.L. Zheng, W.D. Yin, and C.K. Tang. 2014. MicroRNA-590 attenuates lipid accumulation and pro-inflammatory cytokine secretion by targeting lipoprotein lipase gene in human THP-1 macrophages. Biochimie 106: 81–90.CrossRefGoogle Scholar
- 16.Li, T.M., S.C. Liu, Y.H. Huang, C.C. Huang, C.J. Hsu, C.H. Tsai, S.W. Wang, and C.H. Tang. 2017. YKL-40-induced inhibition of miR-590-3p promotes interleukin-18 expression and angiogenesis of endothelial progenitor cells. International Journal of Molecular Sciences 18.Google Scholar
- 19.Liu, J., J. Xu, H. Li, C. Sun, L. Yu, Y. Li, C. Shi, et al. 2015. miR-146b-5p functions as a tumor suppressor by targeting TRAF6 and predicts the prognosis of human gliomas. Oncotarget 6: 29129–29142.Google Scholar
- 27.Ma, H., X. Wang, T. Ha, M. Gao, L. Liu, R. Wang, K. Yu, J.H. Kalbfleisch, R.L. Kao, D.L. Williams, and C. Li. 2016. MicroRNA-125b prevents cardiac dysfunction in polymicrobial sepsis by targeting TRAF6-mediated nuclear factor kappaB activation and p53-mediated apoptotic signaling. The Journal of Infectious Diseases 214: 1773–1783.CrossRefGoogle Scholar
- 28.Meng, Q., W. Zhang, X. Xu, J. Li, H. Mu, X. Liu, L. Qin, X. Zhu, and M. Zheng. 2018. The effects of TRAF6 on proliferation, apoptosis and invasion in osteosarcoma are regulated by miR-124. International Journal of Molecular Medicine 41: 2968–2976.Google Scholar
- 38.Wu, T., Y. Xiang, Y. Lv, D. Li, L. Yu, and R. Guo. 2017. miR-590-3p mediates the protective effect of curcumin on injured endothelial cells induced by angiotensin II. American Journal of Translational Research 9: 289–300.Google Scholar
- 39.Wu, Y., L.T. Song, J.S. Li, D.W. Zhu, S.Y. Jiang, and J.Y. Deng. 2017. MicroRNA-126 regulates inflammatory cytokine secretion in human gingival fibroblasts under high glucose via targeting tumor necrosis factor receptor associated factor 6. Journal of Periodontology 88: e179–e187.CrossRefGoogle Scholar
- 42.Xu, L., P. Zhang, H. Guan, Z. Huang, X. He, X. Wan, H. Xiao, and Y. Li. 2016. Vitamin D and its receptor regulate lipopolysaccharide-induced transforming growth factor-beta, angiotensinogen expression and podocytes apoptosis through the nuclear factor-kappaB pathway. Journal of Diabetes Investigation 7: 680–688.CrossRefGoogle Scholar
- 45.Zapata, J.M., M. Krajewska, S. Krajewski, S. Kitada, K. Welsh, A. Monks, N. McCloskey, J. Gordon, T.J. Kipps, R.D. Gascoyne, A. Shabaik, and J.C. Reed. 2000. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. Journal of Immunology 165: 5084–5096.CrossRefGoogle Scholar
- 48.Zhang, S., J. Ma, L. Sheng, D. Zhang, X. Chen, J. Yang, and D. Wang. 2017. Total coumarins from Hydrangea paniculata show renal protective effects in lipopolysaccharide-induced acute kidney injury via anti-inflammatory and antioxidant activities. Frontiers in Pharmacology 8: 872.CrossRefGoogle Scholar